Skip to content
TrialScanner

NCT02960594

hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse

Phase 1CompletedINOLead

Registry record

Lead sponsor
Inovio Pharmaceuticals
Conditions
Breast Cancer; Lung Cancer; Pancreatic Cancer; Head and Neck Cancer; Ovarian Cancer
Primary completion
Nov 9, 2018Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02960594 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02960594: hTERT Immunotherapy Alone or... | TrialScanner